Introduction
============

Cerebral palsy describes a group of disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, cognition, communication, perception, and/or behavior, and/or by a seizure disorder.[@b1-tcrm-6-585] Cerebral palsy is the most common cause of physical disability in childhood.[@b2-tcrm-6-585] The estimated prevalence of cerebral palsy in the general population is 2/1000,[@b3-tcrm-6-585] and the cumulative incidence rate of cerebral palsy in the age group 5--7 years is 2.7/1000.[@b3-tcrm-6-585] Major causes of cerebral palsy involve prematurity (40%--50% of cases), abnormal intrauterine development due to fetal-maternal infections, asphyxia during delivery, brain trauma during labor and delivery, and complications in the perinatal period.[@b4-tcrm-6-585] Independent of causal factors responsible for the development of cerebral palsy, the disease has a strong socioeconomic impact.[@b5-tcrm-6-585] Currently there is no cure for cerebral palsy, and the therapeutic approaches of physical therapy, occupational therapy, speech therapy, neuropsychology, pharmacology, and surgery achieve only partial benefits for affected individuals.[@b3-tcrm-6-585]

It has been shown that children with cerebral palsy often have poor linear growth during childhood, resulting in a diminished final adult height,[@b6-tcrm-6-585] an issue that has received little attention so far.[@b6-tcrm-6-585]--[@b10-tcrm-6-585] In the studies that have been reported, the investigators have demonstrated that children with cerebral palsy show cerebral palsy deficient growth hormone secretion, by using provocative tests for growth hormone, that insulin-like growth factor (IGF-1) and low growth hormone levels in children with cerebral palsy may explain their low height and that decreased plasma IGF-1 and IGF binding protein 3 (IGFBP3) levels are associated with osteopenia in children with cerebral palsy.[@b6-tcrm-6-585]--[@b10-tcrm-6-585] We have previously shown that 70% of a population of 46 children with cerebral palsy lacked normal growth hormone secretion.[@b3-tcrm-6-585] Among the phenomena that could cause impaired growth hormone secretion are the presence of an altered pool of neurotransmitters, psychosocial deprivation, or suboptimal nutritional status.[@b3-tcrm-6-585]

Neural plasticity and regeneration of the brain, in response to both neurologic injury and different neurological stimulations have been widely demonstrated in animal models[@b11-tcrm-6-585]--[@b14-tcrm-6-585] and in clinical studies using imaging techniques,[@b15-tcrm-6-585]--[@b18-tcrm-6-585] electro-physiologic assessments,[@b19-tcrm-6-585],[@b20-tcrm-6-585] and clinical tests.[@b21-tcrm-6-585]--[@b25-tcrm-6-585] Moreover, it has been reported that the mechanisms of plasticity are increased in the developing central nervous system, so that children who suffer injury at this stage could achieve more complete recovery than adult patients.[@b26-tcrm-6-585]

Several hormones play a role in the recovery from brain injuries, acting either on neurogenesis and/or neural plasticity. Among these, the growth hormone-IGF-1 system seems to be very important for inducing adult neurogenesis and increasing brain plasticity.[@b3-tcrm-6-585] Growth hormone and IGF-1 and their receptors are expressed locally in the brain[@b27-tcrm-6-585]--[@b36-tcrm-6-585] and both hormones can cross the blood--brain barrier. [@b36-tcrm-6-585] Thus, besides its role in several metabolic processes, it has been shown that the growth hormone- IGF-1 axis exerts multiple and important neurotrophic effects related to cell proliferation and survival, both in the central and peripheral nervous system.[@b3-tcrm-6-585],[@b36-tcrm-6-585] In fact, a number of studies have demonstrated that this endocrine axis induces strong proliferation of neural cell precursors in major neurogenic niches, under both physiologic and pathologic conditions.[@b35-tcrm-6-585],[@b37-tcrm-6-585]--[@b39-tcrm-6-585] Moreover, growth hormone expression is increased in the affected brain hemisphere after an ischemic injury.[@b40-tcrm-6-585],[@b41-tcrm-6-585] On the other hand, we demonstrated, for the first time, that growth hormone is an important factor for cell survival.[@b42-tcrm-6-585] Thus, both growth hormone and IGF-1 display marked neuroprotective[@b43-tcrm-6-585],[@b44-tcrm-6-585] and antiapoptotic[@b45-tcrm-6-585]--[@b47-tcrm-6-585] effects.

In a previous study we postulated that growth hormone replacement therapy might be useful in the treatment of children with cerebral palsy, not only for achieving a more normal height but also for correcting some of the neurologic disorders that these patients suffer.[@b3-tcrm-6-585] This study was designed to test this hypothesis, and evaluated the effects of growth hormone treatment combined with physical rehabilitation in the recovery of gross motor function in children with growth hormone deficiency and cerebral palsy as compared with the effects obtained in a similar population of cerebral palsy children without growth hormone deficiency and treated only with physical rehabilitation. Despite the fact that exercise is a powerful stimulus for pituitary growth hormone secretion, cerebral palsy children without growth hormone deficiency subjected to intense physical therapy rehabilitation do not achieve significant improvements. We studied the effects of growth hormone therapy in children with cerebral palsy and growth hormone deficiency as compared with those obtained in children with cerebral palsy and without growth hormone deficiency subjected to the same physical rehabilitation. The rationale for this was to test whether or not exogenous growth hormone administration plays a role in neurogenesis and/or brain plasticity.

Method
======

Participants
------------

The study was conducted in 20 children with cerebral palsy, comprising nine males and 11 females, aged 4.0--10.5 years, who attended the Medical Center Proyecto Foltra for physical and cognitive rehabilitation, selected from a population of 46 cerebral palsy children.[@b3-tcrm-6-585] The reason for selecting 20 children from 46 was to achieve the best possible match between the groups with regard to age, gender, disabilities exhibited, and clinical history. The selection was made by the principal investigator, and none of the therapists knew whether or not the children selected had growth hormone deficiency. All patients were Level IV or V according to the Gross Motor Function Classification System.[@b48-tcrm-6-585] Ten of these cerebral palsy children had been previously detected to have growth hormone deficiency,[@b3-tcrm-6-585] and comprised the study group. The main characteristics of the patients in each group studied are shown in [Tables 1](#t1-tcrm-6-585){ref-type="table"} and [2](#t2-tcrm-6-585){ref-type="table"}.

Treatment of growth hormone deficiency
--------------------------------------

After obtaining informed consent from their parents, the children with cerebral palsy and growth hormone deficiency were given growth hormone (rhGH, Omnitrope^®^, Sandoz) 0.3 μg/kg/day subcutaneously for five days per week at 10.30 pm for two months). Growth hormone administration commenced when physical rehabilitation started.

Blood sample analyses was performed for routine hematology and biochemistry parameters. Baseline anterior pituitary hormone secretion and plasma levels of free T4 were measured by chemiluminescence assays. In addition, fasting plasma IGF-1 and IGFBP3 were measured by solid-phase, enzyme-labeled chemiluminescent immunometric assay (Inmulite 2000, Siemens). These analyses were carried out before commencing the study and at the end of the study.

Clinical assessment
-------------------

To assess motor function in our patients, we used a widely recognized test, the Gross Motor Function Measure (GMFM-88).[@b49-tcrm-6-585] The GMFM-88 is a scale constructed for evaluation of change in gross motor function in children with cerebral palsy. The GMFM-88 consists of 88 items grouped into five dimensions, ie, dimension A (lying and rolling, 17 items), dimension B (sitting, 20 items), dimension C (crawling and kneeling, 14 items), dimension D (standing, 13 items) and dimension E (walking, running, and jumping, 24 items). Scores for each dimension are expressed as a percentage of the maximum score for that dimension, adding the scores for all dimensions, and dividing by 5 to obtain the total score. The reliability, validity, and responsiveness of the GMFM-88 scores are documented for children with cerebral palsy.[@b50-tcrm-6-585] We also used the Modified Ashworth Scale[@b51-tcrm-6-585] to measure spasticity in our spastic patients. The GMFM-88 and Modified Ashworth Scale were performed before commencing the treatment and after two months of treatment.

Intervention
------------

All patients received physical rehabilitation, which was carried out for 45 minutes per day, five days per week, for two months. The therapy basically involved psychomotor and postural re-education based on neurodevelopmental reactions, phases, and processes (ie, neurodevelopmental therapy), and its contents were adapted to the specific needs of each patient, depending on the initial clinical assessment. In general, the treatment was aimed at normalizing muscle tone and improving normal postural reactions, postural control of head and trunk, balance, upper limb motor function, and mobility.

To avoid any kind of bias, each therapist was assigned to treat children having cerebral palsy with or without growth hormone deficiency, without knowing their growth hormone status. The Modified Ashworth scale of spasticity was analyzed by one of the physiotherapists who did not know the growth hormone status of the patient he was examining. Both groups of patients received the same type and duration of physical rehabilitation.

Data analysis
-------------

Pre- and post-treatment data from the GMFM-88 were compared using a nonparametric test for two related samples (Wilcoxon signed-rank test and Mann-Whitney *U* test). Data from the Modified Ashworth Scale were analyzed descriptively.

Results
=======

In the study group, combined treatment using rhGH and physical rehabilitation led to significant improvements in dimension A (lying and rolling, *P* \< 0.02), dimension B (sitting, *P* \< 0.02), dimension C (crawling and kneeling, *P* \< 0.02), and the total score of the GMFM-88 (*P* \< 0.01); dimension D (standing) and dimension E (walking, running, and jumping) did not increase ([Figure 1B](#f1-tcrm-6-585){ref-type="fig"} and [Table 3](#t3-tcrm-6-585){ref-type="table"}). Moreover, four of five spastic patients showed a reduction in their spasticity as measured by the Modified Ashworth Scale ([Table 4](#t4-tcrm-6-585){ref-type="table"}). However, no significant changes were observed in any of these dimensions in the control group, although the total score significantly increased in these children ([Figure 1A](#f1-tcrm-6-585){ref-type="fig"} and [Table 3](#t3-tcrm-6-585){ref-type="table"}), and their spasticity was not improved (data not shown).

The differences between the improvements achieved at the end of the two-month treatment period for both groups are shown in [Figure 2](#f2-tcrm-6-585){ref-type="fig"} and [Table 3](#t3-tcrm-6-585){ref-type="table"}. Clearly, as these data show, children with cerebral palsy and growth hormone deficiency achieved significant improvements in dimensions A, B, and C, and in total score than the control children with cerebral palsy.

Growth hormone administration did not produce any secondary clinical effects. Plasma IGF-1 levels were not significantly different between the two groups of children at the end of the treatment period, and plasma cholesterol levels decreased significantly (*P* \< 0.05) in children with cerebral palsy and growth hormone deficiency.

Discussion
==========

Our results show that combined treatment using rhGH and physical rehabilitation leads to significant improvements in gross motor functions, including lying, rolling, sitting, crawling, and kneeling. All this tasks are contained in the normal ontogeny of human movement, and are important to be able to perform daily activities. However, other gross motor functioning, such as standing, walking, running, and jumping did not improve. This could be due to the brief duration of treatment and the subjects' high level in the Gross Motor Function Classification System, such that they were not able to perform more complex motor tasks. Future studies with larger populations and a longer duration of treatment may be able to demonstrate differences in all motor functions tested.

Spasticity is defined as resistance to passive movement of the joints and is a key component of the so-called upper motor neuron syndrome.[@b52-tcrm-6-585] Spasticity, in its broadest clinical sense, has been linked to various motoneuronal,[@b53-tcrm-6-585] spinal,[@b54-tcrm-6-585] and supraspinal[@b52-tcrm-6-585],[@b55-tcrm-6-585] pathophysiologic phenomena. Thus, we can assume that the reduction in post-treatment spasticity in four of five spastic patients could be related to the efficacy of the treatment used to achieve normalization of the balance of supraspinal inhibitory and excitatory signals,[@b52-tcrm-6-585],[@b55-tcrm-6-585] of the secondary structural and functional changes that occur at cellular level in the spinal cord itself below the level of the injury,[@b54-tcrm-6-585] and/or of the voltage-dependent persistent intrinsic motoneuronal inflows.[@b53-tcrm-6-585]

The new physiotherapy concept, including whole body vibration, physiotherapy, resistance training, and treadmill training, without drug treatment for six months, had a significant and positive effect on bone mineral density, muscle force, and gross motor function in bilaterally spastic children with cerebral palsy.[@b56-tcrm-6-585] However, a systematic review did not find a statistically significant effect of partial bodyweight- supported treadmill training in children with cerebral palsy, despite improvements in gross motor function. [@b57-tcrm-6-585] In a review of randomized controlled trials on physical therapy interventions in children with cerebral palsy, it was shown that some methods (such as neurodevelopmental therapy) were moderately effective in improving motor function in the upper extremities, walking speed, and stride amplitude. However, conflicting evidence was found for the effect of strength training on gross motor function.[@b58-tcrm-6-585] Similarly, a meta-analysis of randomized trials demonstrated that muscle strengthening had a small statistically significant, but not clinically meaningful, effect on gross motor function.[@b59-tcrm-6-585]

On the other hand, some studies have described the effects of growth hormone replacement in children with cerebral palsy. However, most of them have only reported growth data and have not assessed any possible functional recovery.[@b6-tcrm-6-585],[@b7-tcrm-6-585],[@b60-tcrm-6-585]

To our knowledge, this study is the first to demonstrate the positive effects of growth hormone administration in the recovery of some motor functions in children with cerebral palsy. Despite the fact that these were observed in children with cerebral palsy and growth hormone deficiency, because plasma IGF-1 values were similar in both groups at the end of the treatment period, it seems clear that exogenous administration of growth hormone was responsible for the effects observed. According to plasma IGF values, growth hormone status was similar in both groups at the end of the treatment period. In this regard, exercise is known to be a powerful stimulus for endogenous growth hormone release, and it has been demonstrated that inhibiting PI3-Akt signaling, one of the pathways by which growth hormone acts,[@b42-tcrm-6-585] blocks exercise-mediated enhancement of adult neurogenesis and synaptic plasticity in rats.[@b61-tcrm-6-585] This may explain the lack of positive effects obtained in children undergoing exhaustive daily physical work, perhaps because possible growth hormone deficiency has not been determined or treated. On the other hand, it has been recently demonstrated that exogenous growth hormone administration induces strong cellular proliferation in rodents with growth hormone deficiency.[@b62-tcrm-6-585] The data observed in our study support our hypothesis about the effects of growth hormone administration.

Thus, we conclude that combined therapy involving growth hormone replacement and physical rehabilitation is a useful therapeutic approach in the recovery of gross motor function in children with cerebral palsy and growth hormone deficiency. We are now carrying out larger and longer studies that will allow us to understand more precisely the effects of hormone treatment on children with cerebral palsy, aimed at improving both endocrine and neurologic disorders in children with cerebral palsy with or without growth hormone deficiency.
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![Clinical data from the GMFM-88.\
**Notes: A)** Control group. **B**) Study group; "A", "B", "C", "D" and "E" in the horizontal axis are the different dimensions of the GMFM-88 and "TOTAL" is the total score of test. We show pre-treatment (white bars) and post-treatment (grey bars) means and standard errors for each specific assessment. Statistical significance was calculated from data obtained in the GMFM-88 before treatment and after 2 months of it (*Wilcoxon signed-rank test*) (\**P* \< 0.05, \*\**P* \< 0.02 and \*\*\**P* \< 0.01).](tcrm-6-585f1){#f1-tcrm-6-585}

![Study group improvements compared with control group improvements\
**Notes:** "A", "B", "C", "D" and "E" in the horizontal axis are the different dimensions of the GMFM-88 and "TOTAL" is the total score of tet test; we show the group's mean rank from *Mann-Whitney U* for control (white bars) and study (grey bars) groups. Statistcal significance was calculated from the percentage of improvement over baseline for each of the dimensions evaluated in the GMFM-88, comparing groups with each other (*Mann-Whitney U*) (\*\*\**P* \< 0.01).](tcrm-6-585f2){#f2-tcrm-6-585}

###### 

Main characteristics of control group patients

  Patient   Age (years)   Gender   CP cause                         Radiologic findings                       Motor impairment   GMFCS level
  --------- ------------- -------- -------------------------------- ----------------------------------------- ------------------ -------------
  1         4.25          M        Postsurgical iatrogenic injury   Intense diffuse cerebral edema            Flaccid TP         V
  2         4.5           F        Perinatal hypoxia                PVL                                       Spastic TP         V
  3         5.75          M        Perinatal hypoxia                Multiple hemorrhagic lesions in PV zone   Spastic TP         V
  4         9             F        Perinatal hypoxia                Multiple hemorrhagic lesions in PV zone   Dystonic TP        V
  5         4.5           F        Prenatal hypoxia                 PVL                                       Spastic TP         V
  6         4             M        Prematurity                      PVL                                       Spastic TP         V
  7         4.5           M        Prematurity                      PVL                                       Spastic TP         V
  8         4.5           F        Perinatal hypoxia                PVL                                       Dystonic TP        V
  9         7.5           M        Prematurity                      PVL                                       Spastic TP         IV
  10        10.5          F        Postsurgical iatrogenic injury   Diffuse cerebral edema                    Dystonic TP        V

**Abbreviations**: F, female; GMFCS, Gross Motor Function Classification System; M, male; CP, cerebral palsy; PV, periventricular; PVL, periventricular leucomalacia; TP, tetraplegia.

###### 

Main characteristics of study group patients

  Patient   Age (years)   Sex   CP cause                          Radiologic findings                                                                         Motor impairment   GMFCS level
  --------- ------------- ----- --------------------------------- ------------------------------------------------------------------------------------------- ------------------ -------------
  1         4.5           F     Perinatal hypoxia                 Multiple hemorrhagic lesions in the thalamus, basal ganglia, and PV region                  Dystonic TP        V
  2         4.5           M     Prematurity                       PVL, nodular morphology due to PO intraparenchymal hematomas                                Spastic TP         V
  3         4             M     Post-surgical iatrogenic injury   Decreased activity and volume in PO cortex, bilateral PO ischemia, diffuse cerebral edema   Flaccid TP         V
  4         9.8           M     Perinatal hypoxia                 PVL                                                                                         Dystonic TP        IV
  5         6             F     Prenatal hypoxia                  PVL                                                                                         Dystonic TP        V
  6         4             F     Prematurity;                      PVL                                                                                         Spastic TP         V
  7         4.2           M     Perinatal hypoxia                 Multicystic encephalopathy                                                                  Spastic TP         V
  8         4.5           F     Perinatal hypoxia                 Less differentiation of structures, intense diffuse cerebral edema                          Spastic TP         V
  9         10.5          F     Prenatal ischemia                 Ulegyria                                                                                    Spastic TP         IV
  10        4.3           F     Perinatal hypoxia                 PVL, corpus callosum hypoplasia                                                             Dystonic TP        V

**Abbreviations:** F, female; GMFCS, Gross Motor Function Classification System; M, male; CP, cerebral palsy; PV, periventricular; PVL, periventricular leucomalacia; PO, parieto-occipital; TP, tetraplegia.

###### 

Results obtained from the GMFM-88

  GMFM-88       Group     Pretreatment mean score (SD)   Post-treatment mean score (SD)   Intragroup significance (Wilcoxon)                     Improvement mean relative to baseline (%)   Group's mean rank (Mann- Whitney)   Intergroup improvement significance (Mann-Whitney)
  ------------- --------- ------------------------------ -------------------------------- ------------------------------------------------------ ------------------------------------------- ----------------------------------- ------------------------------------------------------
  Dimension A   Control   40.39 (36.88)                  41.17 (36.98)                    ns                                                     5.5                                         6.9                                 0.004[\*\*\*](#tfn6-tcrm-6-585){ref-type="table-fn"}
                Study     38.82 (37.63)                  71.76 (29.53)                    0.012[\*\*](#tfn5-tcrm-6-585){ref-type="table-fn"}     222.79                                      14.1                                
  Dimension B   Control   13.16 (12.84)                  13.66 (12.51)                    ns                                                     15                                          6.8                                 0.002[\*\*\*](#tfn6-tcrm-6-585){ref-type="table-fn"}
                Study     12 (13.46)                     29 (22.67)                       0.012[\*\*](#tfn5-tcrm-6-585){ref-type="table-fn"}     13535.48                                    14.2                                
  Dimension C   Control   9.52 (13.6)                    10.23 (13.51)                    ns                                                     15                                          6.75                                0.002[\*\*\*](#tfn6-tcrm-6-585){ref-type="table-fn"}
                Study     6.9 (11.41)                    20.71 (19.95)                    0.012[\*\*](#tfn5-tcrm-6-585){ref-type="table-fn"}     33457.5                                     14.25                               
  Dimension D   Control   2.05 (2.91)                    3.07 (5.09)                      ns                                                     20                                          11.55                               ns
                Study     1.53 (2.75)                    6.92 (13.83)                     ns                                                     15426.28                                    9.45                                
  Dimension E   Control   1.25 (2.81)                    1.52 (3.61)                      ns                                                     0                                           11.5                                ns
                Study     1.25 (2.81)                    2.77 (6)                         ns                                                     33.3                                        9.5                                 
  Total score   Control   13.27 (12.18)                  13.93 (12.12)                    0.043[\*](#tfn4-tcrm-6-585){ref-type="table-fn"}       10.24                                       14.8                                0.001[\*\*\*](#tfn6-tcrm-6-585){ref-type="table-fn"}
                Study     12.10 (12.25)                  26.23 (16.1)                     0.005[\*\*\*](#tfn6-tcrm-6-585){ref-type="table-fn"}   218.72                                      6.2                                 

**Notes:** The different dimensions involved in the GMFM-88 are shown in the first column. The fifth column shows the statistical significance from data obtained in the GMFM-88 before treatment compared with that two months after commencing it (Wilcoxon signed-rank test). The seventh and eighth columns show the group's mean rank and the statistical significance from the improvement mean relative to baseline (%) (sixth column), comparing each group with the other (Mann*-*Whitney U).

*P* \< 0.05;

*P* \< 0.02;

*P* \< 0.01.

**Abbreviations:** GMFM-88, gross motor function measure; SD, standard deviation; ns, not significant.

###### 

Results obtained from the modified ashworth scale in spastic patients from the study group

  Patient   Pretreatment   Post-treatment
  --------- -------------- ----------------
  2         2              1+
  6         3              1+
  7         4              3
  8         4              3
  9         1+             1+
